As the mechanistic target of rapamycin (mTOR) pathway [17] and glycolysis [18] also contribute to supporting tumor recurrence and chemoresistance, these signaling pathways have become appealing targets for HER2-positive breast cancer therapy. The gene discussed is ERBB2; the disease is neoplasm.